GetClariMedRecherchen nahtlos fortsetzen
30 Sek mit Email - kein Passwort, kein Formular. Ihr Verlauf bleibt auf jedem Gerät.
Verlauf
Keine Anfragen
Psychiatrie-Leitlinien
GetClariMed durchsucht psychiatrische Leitlinien von AWMF, DGPPN und internationalen Fachgesellschaften. Quellenbasierte Antworten zu Psychopharmakotherapie, Dosierungen, Wechselwirkungen und akuter Psychiatrie.
Jetzt kostenlos suchenEvidenzbasiert · Kostenlos · Ohne Anmeldung · DSGVO-konform
Typische Leitlinienfragen
Beispiele, wie sich dieses Fachgebiet in GetClariMed durchsuchen lässt
“Valproat und Lamotrigin - Interaktion und Aufdosierung laut Fachinformation”
“Antidepressiva in der Stillzeit”
“Umstellung zwischen Paliperidon-Depot und Risperidon - Fachinformation und Leitlinie”
“Dissoziative Krampfanfälle - Therapie akut”
“Akute Psychose - präklinische Behandlungsoptionen”
Jede Anfrage erhält eine evidenzbasierte Antwort mit direktem Link zur Originalleitlinie.
Probieren Sie es aus
Valproat und Lamotrigin - Interaktion und Aufdosierung laut Fachinformation
Psychiatrie-Leitlinien auf GetClariMed
334 Leitlinien mit redaktioneller Zusammenfassung
AWMFS2k-Leitlinie Stationäre Interdisziplinäre Multimodale Schmerztherapie (IMST) bei Kindern und Jugendlichen (S2k)AWMFS3-Leitlinie PTBS (AWMF 155-001)2026CochraneCochrane Review: Diagnostic tests for autism spectrum disorder (ASD) in preschool childrenCochraneCochrane Review: Face-to-face psychoeducation for the parents of people with severe mental illnessDGPPNS3-Leitlinie DemenzenAkdÄAkdÄ: Information des BfArM zum Lieferengpass von Zypadhera (Olanzapinpamoat-Monohydrat Pulver und Lösungsmittel zur Herstellung einer2025AkdÄAkdÄ: Rote-Hand-Brief zu Clozapin: Überarbeitete Empfehlungen zur routinemäßigen Blutbildkontrolle im Hinblick auf das Risiko einer AgranulozytoseDrug2025AkdÄAkdÄ: Rote-Hand-Brief zu Finasterid, Dutasterid: Neue Maßnahmen zur Minimierung des Risikos für Suizidgedanken2025AWMFAWMF 038-020: S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen2025AWMFS3-Leitlinie Opioidbezogene Störungen2025AWMFS3-Leitlinie Pathologisches Glücksspiel und Glücksspielstörung2025AWMFS3-Leitlinie Schizophrenie (AWMF 038-009, 2025)2025BfArMAtomoxetin: Neue Warnhinweise zu Serotoninsyndrom und Mordgedanken2025CochraneCochrane Review: Acupuncture for insomnia in people with cancer2025CochraneCochrane Review: Beck Anxiety Inventory (BAI) for detecting anxiety disorders in adults2025CochraneCochrane Review: Breastfeeding interventions for preventing postpartum depression2025CochraneCochrane Review: Cognitive behavioural therapy for insomnia in people with cancer2025CochraneCochrane Review: Combined pharmacological and psychosocial interventions for alcohol use disorder2025CochraneCochrane Review: Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults2025CochraneCochrane Review: Home visiting for postpartum depression2025CochraneCochrane Review: Hospital Anxiety and Depression Scale Anxiety subscale (HADS-A) for detecting anxiety disorders in adults2025CochraneCochrane Review: Interventions for helping people recognise early signs of recurrence in bipolar disorder2025CochraneCochrane Review: Lurasidone versus typical antipsychotics for schizophrenia2025CochraneCochrane Review: Music-based therapeutic interventions for people with dementia2025CochraneCochrane Review: Opioid agonist therapy for opioid use disorder in primary versus specialty care2025CochraneCochrane Review: Pharmacotherapies for cannabis use disorder2025CochraneCochrane Review: Post-incident debriefing for people with schizophrenia after coercive measures2025CochraneCochrane Review: State-Trait Anxiety Inventory (STAI) for detecting anxiety disorders in adults2025CochraneCochrane Review: Sustained-release naltrexone for opioid dependence2025CochraneCochrane Review: Switching antipsychotics versus continued current treatment in people with non-responsive schizophrenia2025DGPPNS2k-Leitlinie Begutachtung psychischer und psychosomatischer Störungen - Interessenkonflikte2025DGPPNS3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen - Tabellenband2025DGPPNS3-Leitlinie/NVL Unipolare Depression - Evidenzbericht2025DGPPNS3-Leitlinie/NVL Unipolare Depression - Interessenkonflikte2025Gemeinsamer Bundesausschuss (G-BA)DMP-Anforderungen-Richtlinie (G-BA) - Konsolidierte Fassung2025WHOGuidance on mental health policy and strategic action plans: Module 4. Country case scenarios2025WHOWHO guideline on HIV service delivery2025Addiction PsychiatryPTSD Severity Influence on Return to Substance Use After Treatment2024AkdÄAkdÄ: „UAW-News International“: Psychiatrische und sexuelle Nebenwirkungen von Finasterid2024AkdÄAkdÄ: Information zu Aripiprazol: pathologisches Spielen2024AkdÄAkdÄ: Information zu Fluorchinolonen: suizidale Gedanken und suizidales Verhalten2024AkdÄAkdÄ: Information zu Pregabalin und Gabapentin: Berichterstattung in den Medien zu Todesfällen2024BfArMValproat: Potenzielles Risiko für neurologische Entwicklungsstörungen bei Kindern von Vätern, die valproathaltige Arzneimittel einnehmen2024CochraneCochrane Review: Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis2024CochraneCochrane Review: Cognitive behavioural therapy and third-wave approaches for anxiety and related disorders in older people2024CochraneCochrane Review: Collaborative care approaches for people with severe mental illness2024CochraneCochrane Review: Disulfiram for the treatment of cocaine dependence2024CochraneCochrane Review: Early pharmacological interventions for prevention of post-traumatic stress disorder (PTSD) in individuals experiencing acute traumatic stress symptoms2024CochraneCochrane Review: Eye movement desensitisation and reprocessing for survivors of life-threatening medical events2024CochraneCochrane Review: Factors that influence participation in physical activity for people with bipolar disorder: a synthesis of qualitative evidence2024CochraneCochrane Review: Family-based interventions versus standard care for people with schizophrenia2024CochraneCochrane Review: Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment2024CochraneCochrane Review: Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders2024CochraneCochrane Review: Non-pharmacological interventions for improving language and communication in people with primary progressive aphasia2024CochraneCochrane Review: Parenteral medication for the management of acute severe behavioural disturbance (ASBD) in the emergency department2024CochraneCochrane Review: Psychological and social interventions for the promotion of mental health in people living in low- and middle-income countries affected by humanitarian crises2024CochraneCochrane Review: Psychosocial interventions for stimulant use disorder2024CochraneCochrane Review: Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults2024CochraneCochrane Review: Risk assessment for aggressive behaviour in schizophrenia2024DGPPNS2k-Leitlinie Einwilligung von Menschen mit Demenz in medizinische Maßnahmen - Interessenkonflikte2024G-BAG-BA Nutzenbewertung: Daridorexant (Erneute Bewertung nach Änderung der Anlage III AM-RL: Schlafstörungen)2024Heart and Stroke Foundation of CanadaCanadian Stroke Best Practice Recommendations: Vascular Cognitive Impairment (7th Edition, 2024)2024IQWiGIQWiG A19-04: Melatonin (Schlafstörungen) - Nutzenbewertung gemäß §35a SGB V2024IQWiGIQWiG A22-34: Nutzenbewertung von Bupropion, Cytisin, Nicotin und Vareniclin zur Tabakentwöhnung bei schwerer Tabakabhängigkeit 2024IQWiGIQWiG HT22-02 : Generalisierte Angststörung: Helfen Apps Betroffenen bei der Bewältigung ihrer Erkrankung?2024RACGPAbuse and violence: Working with our patients in general practice (White Book)2024RACGPPrescribing drugs of dependence in general practice2024WHOFacilitation manual: psychological first aid during Ebola virus disease outbreaks, 2nd edition2024WHOMental health of children and young people: service guidance2024APAAPA Practice Guidelines for the Treatment of Eating Disorders2023AWMFNationale VersorgungsLeitlinie Unipolare Depression (NVL, 2023)2023CochraneCochrane Review: Acetylcholinesterase inhibitors for autistic spectrum disorders2023CochraneCochrane Review: Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment2023CochraneCochrane Review: Antidepressants for the treatment of depression in people with cancer2023CochraneCochrane Review: Baclofen for alcohol use disorder2023CochraneCochrane Review: Behavioural and cognitive-behavioural interventions for outwardly directed aggressive behaviour in people with intellectual disabilities2023CochraneCochrane Review: Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia2023CochraneCochrane Review: Cognitive rehabilitation for people with mild to moderate dementia2023CochraneCochrane Review: Dance movement therapy for dementia2023CochraneCochrane Review: Interventions from pregnancy to two years after birth for parents experiencing complex post-traumatic stress disorder and/or with childhood experience of maltreatment2023CochraneCochrane Review: Magnetic seizure therapy for people with schizophrenia2023CochraneCochrane Review: Mental Health First Aid as a tool for improving mental health and well-being2023CochraneCochrane Review: Methods for informing people with amyotrophic lateral sclerosis/motor neuron disease of their diagnosis2023CochraneCochrane Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)2023CochraneCochrane Review: Motivational interviewing for substance use reduction2023CochraneCochrane Review: Non-pharmacological interventions for sleep disturbances in people with dementia2023CochraneCochrane Review: Pharmacological treatments in panic disorder in adults: a network meta-analysis2023CochraneCochrane Review: Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents2023CochraneCochrane Review: Primary-level and community worker interventions for the prevention of mental disorders and the promotion of well-being in low- and middle-income countries2023CochraneCochrane Review: Psychological interventions for depression in adolescent and adult congenital heart disease2023CochraneCochrane Review: Psychological interventions for women with non-metastatic breast cancer2023CochraneCochrane Review: Psychological therapies delivered remotely for the management of chronic pain (excluding headache) in adults2023CochraneCochrane Review: Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries2023DGPPNS3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung2023DGPPNS3-Leitlinie Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung - Interessenkonflikte2023DGPPNS3-Leitlinie/NVL Unipolare Depression - Was ist neu?2023G-BAG-BA Nutzenbewertung: Esketamin (Neubewertung nach Fristablauf: Depression, therapieresistent, in Kombination mit SSRI oder SNRI)2023IQWiGIQWiG A23-18: Esketamin (therapieresistente Major Depression) – Nutzenbewertung gemäß § 35a SGB V2023IQWiGIQWiG A23-75: Esketamin (therapieresistente Major Depression) – Addendum zum Auftrag A23-182023IQWiGIQWiG HT21-02: Burnout: Kann Yoga bei der Bewältigung helfen? 2023IQWiGIQWiG V22-01: Leitliniensynopse für die Aktualisierung des DMP Depression 2023SIGNSIGN 168: Assessment, Diagnosis, Care and Support for People with Dementia and Their Carers2023SIGNSIGN 169: Perinatal mental health conditions2023USPSTFScreening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement.2023USPSTFScreening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement.2023USPSTFUSPSTF Recommendation: Screening for Depression in Adults2023USPSTFUSPSTF: Anxiety Disorders in Adults: Screening (Grade B, 2023)2023USPSTFUSPSTF: Anxiety Disorders in Adults: Screening (Grade B)2023USPSTFUSPSTF: Depression and Suicide Risk in Adults: Screening (Grade B, 2023)2023WHOMental health, human rights and legislation: guidance and practice2023WHOWHO framework for meaningful engagement of people living with noncommunicable diseases, and mental health and neurological conditions2023WHOWHO Guide to Mental Health in Primary Care (Depression)2023WHOWHO Guidelines on Management of Substance Abuse2023WHOWHO guidelines on parenting interventions to prevent maltreatment and enhance parent–child relationships with children aged 0–17 years: web annex2023WHOWHO Mental Health Gap Action Programme (mhGAP) Guidelines2023WHOWHO operational handbook on tuberculosis: module 6: tuberculosis and comorbidities: mental health conditions2023WHOWHO EML 2023: Section 13 - Psychotherapeutic Medicines2023AWMFNicht-alkoholische Fettlebererkrankungen2022AWMFS3-Leitlinie Borderline-Persönlichkeitsstörung2022AWMFS3-Leitlinie Umgang mit Patienten mit nicht-spezifischen, funktionellen und somatoformen Körperbeschwerden2022CochraneCochrane Review: Algorithm-based pain management for people with dementia in nursing homes2022CochraneCochrane Review: Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia2022CochraneCochrane Review: Antipsychotic dose reduction compared to dose continuation for people with schizophrenia2022CochraneCochrane Review: Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia2022CochraneCochrane Review: Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms2022CochraneCochrane Review: Cognitive behavioural therapy (group) for schizophrenia2022CochraneCochrane Review: Control interventions in randomised trials among people with mental health disorders2022CochraneCochrane Review: Diagnostic test accuracy of remote, multidomain cognitive assessment (telephone and video call) for dementia2022CochraneCochrane Review: Early pharmacological interventions for universal prevention of post-traumatic stress disorder (PTSD)2022CochraneCochrane Review: Memantine for autism spectrum disorder2022CochraneCochrane Review: Music therapy for autistic people2022CochraneCochrane Review: Music therapy for people with substance use disorders2022CochraneCochrane Review: Opioid agonist treatment for people who are dependent on pharmaceutical opioids2022CochraneCochrane Review: Overall prognosis of preschool autism spectrum disorder diagnoses2022CochraneCochrane Review: Pharmaceutical interventions for emotionalism after stroke2022CochraneCochrane Review: Pharmacological interventions for people with borderline personality disorder2022CochraneCochrane Review: Pharmacological interventions for prevention of weight gain in people with schizophrenia2022CochraneCochrane Review: Pharmacological interventions for the treatment of disordered and problem gambling2022CochraneCochrane Review: Pharmacotherapy for post traumatic stress disorder (PTSD)2022CochraneCochrane Review: Psychological treatments for depression and anxiety in dementia and mild cognitive impairment2022CochraneCochrane Review: Shared decision-making interventions for people with mental health conditions2022CochraneCochrane Review: Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy2022DGPPNS3-Leitlinie Kindesmisshandlung, -missbrauch und -vernachlässigung (Kinderschutzleitlinie)2022DGPPNS3-Leitlinie Zwangsstörungen2022G-BAG-BA Nutzenbewertung: Daridorexant (Schlafstörungen, Anwendung bis zu 4 Wochen)2022IQWiGIQWiG HT19-04: Depressionen bei Kindern und Jugendlichen: Führt Psychotherapie im Vergleich zu anderen Therapien zu besseren Ergebnissen?2022IQWiGIQWiG HT20-02: Herzerkrankung bei Kindern: Können Kinder durch eine psychologische Begleitung bei der Bewältigung ihrer Krankheit unterstützt werden?2022SIGNSIGN 164: Eating Disorders2022USPSTFScreening for Anxiety in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.2022USPSTFScreening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.2022WHOGuidelines on mental health at work2022WHOMental health at work: policy brief2022WHOWHO Guidelines on Mental Health at Work2022ACEPClinical Policy: Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the ED2021AWMFAWMF 021-020: S3-Leitlinie Divertikelkrankheit / Divertikulitis2021AWMFS3-Leitlinie Tabakkonsum (AWMF 076-006)2021CochraneCochrane Review: Anticholinergic drugs and dementia: time for transparency in the face of uncertainty2021CochraneCochrane Review: Antidepressants for functional abdominal pain disorders in children and adolescents2021CochraneCochrane Review: Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia2021CochraneCochrane Review: Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults2021CochraneCochrane Review: Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)2021CochraneCochrane Review: Cannabinoids for the treatment of dementia2021CochraneCochrane Review: Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis2021CochraneCochrane Review: Humour-based interventions for people with schizophrenia2021CochraneCochrane Review: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults2021CochraneCochrane Review: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within a secondary care setting2021CochraneCochrane Review: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early detection of dementia across a variety of healthcare settings2021CochraneCochrane Review: Internet-based cognitive and behavioural therapies for post-traumatic stress disorder (PTSD) in adults2021CochraneCochrane Review: Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries2021CochraneCochrane Review: Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder2021CochraneCochrane Review: Lamotrigine in the maintenance treatment of bipolar disorder2021CochraneCochrane Review: Magnetic seizure therapy for treatment-resistant depression2021CochraneCochrane Review: Medications for daytime sleepiness in individuals with idiopathic hypersomnia2021CochraneCochrane Review: Mindfulness-based interventions for substance use disorders2021CochraneCochrane Review: Mini-Cog for the detection of dementia within a primary care setting2021CochraneCochrane Review: Mini-Cog for the detection of dementia within a secondary care setting2021CochraneCochrane Review: Music interventions for improving psychological and physical outcomes in people with cancer2021CochraneCochrane Review: New generation antidepressants for depression in children and adolescents: a network meta-analysis2021CochraneCochrane Review: Palliative care interventions in advanced dementia2021CochraneCochrane Review: Parenting interventions for people with schizophrenia or related serious mental illness2021CochraneCochrane Review: Pharmacological treatment for psychotic depression2021CochraneCochrane Review: Pharmacotherapy for trichotillomania2021CochraneCochrane Review: Pre-deployment programmes for building resilience in military and frontline emergency service personnel2021CochraneCochrane Review: Prevention of depression in adults with long-term physical conditions2021CochraneCochrane Review: Primary-level worker interventions for the care of people living with mental disorders and distress in low- and middle-income countries2021CochraneCochrane Review: Prognostic models for predicting relapse or recurrence of major depressive disorder in adults2021CochraneCochrane Review: Psychological and pharmacological interventions for depression in patients with coronary artery disease2021CochraneCochrane Review: Psychological interventions for treating foot ulcers, and preventing their recurrence, in people with diabetes2021CochraneCochrane Review: Remotely delivered information, training and support for informal caregivers of people with dementia2021CochraneCochrane Review: Second-generation antidepressants for treatment of seasonal affective disorder2021CochraneCochrane Review: Smoking cessation for improving mental health2021CochraneCochrane Review: The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder2021CochraneCochrane Review: Video games for people with schizophrenia2021CochraneCochrane Review: Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia2021DGPPNS3-Leitlinie Posttraumatische Belastungsstörung (PTBS)2021DGPPNS3-Leitlinie Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung2021DGPPNS3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen - Tabellenband - Interessenkonflikte2021G-BAG-BA Nutzenbewertung: Esketamin (Bekannter Wirkstoff mit neuem Unterlagenschutz: Depression, akute Kurzzeitbehandlung, Kombinationstherapie)2021G-BAG-BA Nutzenbewertung: Esketamin (Bekannter Wirkstoff mit neuem Unterlagenschutz: Depression, therapieresistent, in Kombination mit SSRI oder SNRI)2021G-BAG-BA Nutzenbewertung: Eszopiclon (Schlafstörungen)2021IQWiGIQWiG A21-24: Esketamin (Depression) - Nutzenbewertung gemäß § 35a SGB V2021IQWiGIQWiG A21-25: Esketamin (Depression, Akutbehandlung) - Nutzenbewertung gemäß § 35a SGB V2021IQWiGIQWiG V20-03: Evidenzrecherche S3-Leitlinie Demenzen2021USPSTFInterventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement.2021WHOGuidance on community mental health services: Promoting person-centred and rights-based approaches2021WHOMental health crisis services: promoting person-centred and rights-based approaches2021WHOMental health investment case: a guidance note2021WHOTeacher's Guide2021AkdÄAkdÄ: Information des BfArM zu Hydroxychloroquin und Chloroquin: Psychiatrische Störungen.2020ATSInitiating Pharmacologic Treatment in Tobacco-Dependent Adults: An Official American Thoracic Society Clinical Practice Guideline2020BfArMHydroxychloroquin und Chloroquin: Psychiatrische Störungen2020CochraneCochrane Review: Alcoholics Anonymous and other 12-step programs for alcohol use disorder2020CochraneCochrane Review: An overview of systematic reviews on mental health promotion, prevention, and treatment of common mental disorders for refugees, asylum seekers, and internally displaced persons2020CochraneCochrane Review: Aromatherapy for dementia2020CochraneCochrane Review: Avatar Therapy for people with schizophrenia or related disorders2020CochraneCochrane Review: Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit2020CochraneCochrane Review: Cognitive behavioural therapy for anxiety disorders in children and adolescents2020CochraneCochrane Review: Cognitive behavioural therapy for tinnitus2020CochraneCochrane Review: Cognitive-behavioural therapy (CBT) interventions for young people aged 10 to 18 with harmful sexual behaviour2020CochraneCochrane Review: Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life2020CochraneCochrane Review: Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders2020CochraneCochrane Review: Drug therapy for delirium in terminally ill adults2020CochraneCochrane Review: Interventions for the management of obesity in people with bipolar disorder2020CochraneCochrane Review: Interventions to improve return to work in depressed people2020CochraneCochrane Review: Interventions to support the resilience and mental health of frontline health and social care professionals during and after a2020CochraneCochrane Review: Maintenance agonist treatments for opiate-dependent pregnant women2020CochraneCochrane Review: Maintenance treatment with antipsychotic drugs for schizophrenia2020CochraneCochrane Review: Pharmacological interventions for antisocial personality disorder2020CochraneCochrane Review: Pharmacological treatment of depression in people with a primary brain tumour2020CochraneCochrane Review: Psychological and social interventions for the prevention of mental disorders in people living in low- and middle-income countries affected by humanitarian crises2020CochraneCochrane Review: Psychological interventions for antisocial personality disorder2020CochraneCochrane Review: Psychological interventions for psychosis in adolescents2020CochraneCochrane Review: Psychological therapies for people with borderline personality disorder2020CochraneCochrane Review: Psychological therapies for women who experience intimate partner violence2020CochraneCochrane Review: Psychosocial interventions for conversion and dissociative disorders in adults2020CochraneCochrane Review: Simulated presence therapy for dementia2020CochraneCochrane Review: Specialised early intervention teams (extended time) for recent-onset psychosis2020CochraneCochrane Review: Specialised early intervention teams for recent-onset psychosis2020CochraneCochrane Review: Video calls for reducing social isolation and loneliness in older people: a rapid review2020DGPPNS3-Leitlinie Posttraumatische Belastungsstörung (PTBS) - Interessenkonflikte2020DGPPN (Deutsche Gesellschaft für Psychiatrie und Psychotherapie)S3-Leitlinie Diagnostik und Therapie Bipolarer Störungen2020IQWiGIQWiG HT17-05: Angststörungen: Führt der ergänzende Einsatz der Eye Movement Desensitization and Reprocessing Therapie bei psychotherapeutischen2020USPSTFPrimary Care Interventions for Prevention and Cessation of Tobacco Use in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.2020USPSTFPrimary Care-Based Interventions to Prevent Illicit Drug Use in Children, Adolescents, and Young Adults: US Preventive Services Task Force Recommendation Statement.2020USPSTFScreening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement.2020AkdÄAkdÄ: Information der Britischen Arzneimittelbehörde zu Montelukast: Risiko von neuropsychiatrischen Reaktionen2019AkdÄAkdÄ: Rote-Hand-Brief zu Belimumab (Benlysta®): Erhöhtes2019AkdÄAkdÄ: Rote-Hand-Brief zu hormonellen Kontrazeptiva: Neuer2019AWMFS3-Leitlinie Behandlung von Adipositas2019AWMFS3-Leitlinie Psychosomatik bei chronischen Schmerzstörungen2019CochraneCochrane Review: Acetylsalicylic acid (aspirin) for schizophrenia2019CochraneCochrane Review: AD-8 for detection of dementia across a variety of healthcare settings2019CochraneCochrane Review: Addenbrooke's Cognitive Examination III (ACE-III) and mini-ACE for the detection of dementia and mild cognitive impairment2019CochraneCochrane Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease2019CochraneCochrane Review: Animal-assisted therapy for dementia2019CochraneCochrane Review: Antidepressants plus benzodiazepines for adults with major depression2019CochraneCochrane Review: Baclofen for alcohol withdrawal2019CochraneCochrane Review: Beginning reading interventions for children and adolescents with intellectual disability2019CochraneCochrane Review: Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses2019CochraneCochrane Review: Cognitive training for people with mild to moderate dementia2019CochraneCochrane Review: Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults2019CochraneCochrane Review: Computerised cognitive training for preventing dementia in people with mild cognitive impairment2019CochraneCochrane Review: Couple and family therapies for post-traumatic stress disorder (PTSD)2019CochraneCochrane Review: Electroconvulsive therapy for treatment-resistant schizophrenia2019CochraneCochrane Review: Family therapy approaches for anorexia nervosa2019CochraneCochrane Review: Haloperidol discontinuation for people with schizophrenia2019CochraneCochrane Review: Human resource management training of supervisors for improving health and well-being of employees2019CochraneCochrane Review: Interventions for female drug-using offenders2019CochraneCochrane Review: Interventions for preventing delirium in older people in institutional long-term care2019CochraneCochrane Review: Interventions for prodromal stage of psychosis2019CochraneCochrane Review: Light therapy for preventing seasonal affective disorder2019CochraneCochrane Review: Lithium for acute mania2019CochraneCochrane Review: Memantine for dementia2019CochraneCochrane Review: Mindfulness-based stress reduction for women diagnosed with breast cancer2019CochraneCochrane Review: Modafinil for people with schizophrenia or related disorders2019CochraneCochrane Review: Multiple session early psychological interventions for the prevention of post-traumatic stress disorder2019CochraneCochrane Review: Pharmacological interventions for the treatment of delirium in critically ill adults2019CochraneCochrane Review: Pharmacotherapies for cannabis dependence2019CochraneCochrane Review: Psychological interventions for co-occurring depression and substance use disorders2019CochraneCochrane Review: Psychological therapies for preventing seasonal affective disorder2019CochraneCochrane Review: Psychological therapies for the prevention of migraine in adults2019CochraneCochrane Review: Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease2019CochraneCochrane Review: Psychosocial interventions for informal caregivers of people living with cancer2019CochraneCochrane Review: Psychosocial interventions for people with both severe mental illness and substance misuse2019CochraneCochrane Review: Psychosocial interventions for preventing and treating depression in dialysis patients2019CochraneCochrane Review: Second-generation antidepressants for preventing seasonal affective disorder in adults2019CochraneCochrane Review: Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery2019CochraneCochrane Review: Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years2019CochraneCochrane Review: Systematic screening and assessment of psychosocial well-being and care needs of people with cancer2019CochraneCochrane Review: Treatments for primary delusional infestation2019CochraneCochrane Review: Yoga as part of a package of care versus non-standard care for schizophrenia2019DGPPNS2k-Leitlinie Einwilligung von Menschen mit Demenz in medizinische Maßnahmen2019DGPPNS3-Leitlinie ADHS bei Kindern, Jugendlichen und Erwachsenen2019DGPPNS3-Leitlinie Kindesmisshandlung, -missbrauch und -vernachlässigung (Kinderschutzleitlinie) - Evidenzbericht2019G-BAG-BA Nutzenbewertung: Lisdexamfetamindimesilat (neues Anwendungsgebiet: Aufmerksamkeitsdefizit-Hyperaktivitäts-Störungen, ≥ 18 Jahre)2019G-BAG-BA Nutzenbewertung: Melatonin2019IQWiGIQWiG A19-40: Lisdexamfetamin (ADHS) - Nutzenbewertung gemäß § 35a SGB V2019SIGNSIGN 157: Risk Reduction and Management of Delirium2019USPSTFInterventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement.2019AkdÄAkdÄ: Information der FDA zu Lamotrigin: Überschießende Reaktion des Immunsystems.2018BfArMSuizidalität als mögliche Folge einer Depression unter der Anwendung hormoneller Kontrazeptiva2018Diabetes CanadaDiabetes Canada Chapter 18: Diabetes and Mental Health2018IQWiGIQWiG A18-25: Cariprazin (Schizophrenie) - Nutzenbewertung gemäß § 35a SGB V2018IQWiGIQWiG A18-50: Cariprazin (Schizophrenie) - Addendum zum Auftrag A18-252018IQWiGIQWiG S16-05: Screening auf Depression2018USPSTFScreening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement.2018USPSTFUSPSTF: Unhealthy Alcohol Use in Adults: Screening and Brief Intervention (Grade B, 2018)2018AkdÄAkdÄ: Information zu Clozapin: Britische Arzneimittelbehörde2017AkdÄAkdÄ: Informationsbrief zu Arzneimitteln, die Valproat und2017AkdÄAkdÄ: Rote-Hand-Brief zu Haldol® (Tabletten, Tropfen zum2017DGPPNS3-Leitlinie Fibromyalgiesyndrom2017IQWiGIQWiG N14-02: Systemische Therapie bei Erwachsenen als Psychotherapieverfahren2017SIGNSIGN 145: Assessment, Diagnosis and Interventions for Autism Spectrum Disorders2016WHOWHO mhGAP Intervention Guide for Mental Health (Version 2.0)2016G-BAG-BA Nutzenbewertung: Vortioxetin (Major Depression)2015IQWiGIQWiG A14-42: Lurasidon - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)2015IQWiGIQWiG A15-16: Vortioxetin - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)2015G-BAG-BA Nutzenbewertung: Lurasidon (Schizophrenie)2014G-BAG-BA Nutzenbewertung: Nalmefen (Reduktion des Alkoholkonsums bei Alkoholabhängigkeit)2014IQWiGIQWiG A14-30: Nalmefen - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)2014G-BAG-BA Nutzenbewertung: Lisdexamfetamindimesilat (Aufmerksamkeitsdefizit-Hyperaktivitäts-Störungen, ≥ 6 bis < 18 Jahre)2013IQWiGIQWiG G09-01: Kosten-Nutzen-Bewertung von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen2013IQWiGIQWiG GA10-01: Pilotstudie Analytic Hierarchy Process in der Indikation Majore Depression2013SIGNSIGN 131: Management of schizophrenia2013IQWiGIQWiG A05-20C: Bupropion, Mirtazapin und Reboxetin zur Behandlung der Depression2011IQWiGIQWiG A05-20A: Selektive Serotonin- und Noradrenalin-Wiederaufnahme-Hemmer (SNRI) zur Behandlung der Depression2010AkdÄAkdÄ Bekanntgabe: Akute psychotische Reaktion nach Amoxicillin/Clavulansäure2009AkdÄAkdÄ Bekanntgabe: Psychiatrische Erkrankungen als unerwünschte Arzneimittelwirkung von Mirena®2009IQWiGIQWiG GA09-01: Leitliniensynopse zum Thema "Depression"2009BfArMAntidepressiva: Erhöhtes Risiko zu suizidalem Verhalten bei Erwachsenen unter 25 Jahren2008BfArMRote-Hand-Brief zu Acomplia®: Europäische Arzneimittelagentur empfiehlt Anwendungsbeschränkungen2007BfArMAntidepressiva: Wissenschaftliche Neubewertung der SSRI/SNRI abgeschlossen - Neue Warnhinweise auf suizidales Verhalten bei Kindern und Jugendlichen2005SIGNSIGN 82: Bipolar affective disorder2005BfArMParoxetin: Als Antidepressivum bei unter 18-Jährigen jetzt kontraindiziert2004
Und über 2.500 weitere Leitlinien aus AWMF, NVL, RKI, WHO u.a.
Häufige Fragen
Ja, GetClariMed liefert leitlinienbasierte Informationen zu Wechselwirkungen, Dosisanpassungen und Kontraindikationen. Suchen Sie z.B. nach "Valproat Lamotrigin Interaktion" oder "Antidepressiva Stillzeit".
Ja, GetClariMed enthält Embryotox-Empfehlungen zur Arzneimittelsicherheit in Schwangerschaft und Stillzeit, zusätzlich zu AWMF und DGPPN-Leitlinien.
Weitere Fachgebiete
Leitlinien-Suche starten
Durchsuchen Sie Psychiatrie-Leitlinien und weitere Quellen — kostenlos und ohne Anmeldung.
Jetzt suchenStand: 8. Oktober 2026